Natera demonstrates MRD test benefit in colorectal cancer patients

Natera presented data demonstrating clinical benefit of its minimal residual disease (MRD) test in colorectal cancer patients at the 2026 ESMO Gastrointestinal Congress in Munich. The test, which detects circulating tumor DNA, showed prognostic value in identifying patients at risk of recurrence. The findings support the diagnostic utility of Natera's MRD assay in post-treatment monitoring of colorectal cancer.